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Abstract The Rho^guanine nucleotide exchange factors (Rho^
GEFs) remodel the actin cytoskeleton via their Rho^GTPase
targets and a¡ect numerous physiological processes such as
transformation and cell motility. They are therefore attractive
targets to design speci¢c inhibitors that may have therapeutic
applications. Trio contains two Rho^GEF domains, GEFD1 and
GEFD2, which activate the Rac and RhoA pathways, respec-
tively. Here we have used a genetic screen in yeast to select in
vivo peptides coupled to thioredoxin, called aptamers, that could
inhibit GEFD2 activity. One aptamer, TRIAPK (TRio Inhibi-
tory APtamer), speci¢cally blocks GEFD2-exchange activity on
RhoA in vitro. The corresponding peptide sequence, TRIPK,
inhibits TrioGEFD2-mediated activation of RhoA in intact cells
and speci¢cally reverts the neurite retraction phenotype induced
by TrioGEFD2 in PC12 cells. Thus TRIPK is the ¢rst Rho^
GEF inhibitor isolated so far, and represents an important step
in the design of inhibitors for the expanding family of Rho^
GEFs. / 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
Key words: Exchange factor; Rho^GTPase; Trio;
Peptide aptamer; PC12 cell
1. Introduction
Rho^GTPases are molecular switches that control actin cy-
toskeleton modi¢cations during proliferation, transformation,
cell migration and morphogenesis [1]. They cycle between an
inactive, GDP-bound form and an active, GTP-bound form.
Guanine nucleotide exchange factors (Rho^GEFs) accelerate
GDP/GTP exchange, rendering the GTPase active [2]. Rho^
GEFs share a conserved catalytic region termed the DH do-
main (for Dbl-homology) in reference to the oncogene Dbl,
which was one of the ¢rst Rho^GEFs characterised [3]. A PH
(Pleckstrin-homology) domain is always associated with the
DH domain, suggesting that the DH^PH tandem is the func-
tional unit in vivo. PH domains are thought to be involved
mainly in subcellular localisation or in the regulation of DH-
dependent exchange activity [4].
Trio is a complex protein containing two Rho^GEF do-
mains of di¡erent speci¢city [5]. The ¢rst domain, Trio-
GEFD1, activates the Rac pathway via RhoG [6], and the
second, TrioGEFD2, acts speci¢cally on RhoA [5], indicating
that Trio is able to link several Rho^GTPase pathways in vivo
[7]. In addition, TrioGEFD1 binds to the actin-binding pro-
teins Filamin and Tara, providing a direct link between Trio
and the actin cytoskeleton [8,9]. Genetic studies of Trio ho-
mologues in Caenorhabditis elegans and Drosophila reveal that
Trio plays a central role in neuronal cell migration and axon
guidance [10^14] via a GEFD1-dependent process. The
knock-out of the mouse Trio gene is lethal and Trio3/3
embryos display defects in neuronal organisation and in
muscle development [15]. Consistently, human Trio induces
neurite outgrowth in PC12 cells and is involved in the nerve
growth factor (NGF) pathway [16].
The large family of Rho^GEFs, like their GTPase targets,
controls a variety of physiological processes, including trans-
formation, metastasis, cell motility and neuronal development
[17]. They are therefore attractive targets to design speci¢c
inhibitors that may have therapeutic applications. To identify
such inhibitors, we utilised a recently developed genetic
screen, allowing the in vivo selection of peptide aptamers
that bind to a target protein and are thus potential inhibitors.
Aptamers are short random peptides fused to the bacterial
protein thioredoxin (Trx), which constrains them. Using
TrioGEFD2 as a bait, we isolated one aptamer, TRIAPK
(TRio Inhibitory APtamer), that speci¢cally inhibited its in
vitro exchange activity towards RhoA. The peptide sequence
corresponding to TRIAPK, TRIPK (Trio Inhibitory Peptide),
bound to TrioGEFD2 in mammalian cells and inhibited
TrioGEFD2-mediated RhoA activation. In addition, TRIPK
blocked TrioGEFD2 activity on neuronal morphology in
PC12 cells but not that of the RhoA-speci¢c GEF domain
of the Trio-like protein Kalirin. In conclusion, this is the ¢rst
report of a speci¢c in vivo inhibitor of a Rho^GEF family
member.
2. Materials and methods
2.1. Peptide aptamer screening and DNA methods
The TrioGEFD2 bait was constructed as follows: plasmid
pMTHATrio5 was digested with EcoRI/XhoI and the insert (encom-
passing aa 1848^2298) cloned in pEG202 EcoRI/XhoI [18]. Yeast
strain EGY048 [18] was transformed with this bait and subsequently
with the library of Trx-constrained aptamers according to standard
procedures. After transformation, cells were allowed to recover for 4 h
in a galactose-containing medium before plating on a selective galac-
tose medium. Of the 2U106 screened colonies, those growing in the
absence of leucine were recovered and retested for interaction. Bind-
ing speci¢city was investigated by screening for interaction with other
baits: TrioDH2 (aa 1848^2096), TrioPH2 (aa 2107^2223), Vav (aa
172^598), Dbl (aa 498^826) and Cdc2 [19].
The sequence of the variable moiety of the aptamer was determined
using an ABIPRISM automated sequencer (Perkin Elmer). For GST
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fusions, selected aptamers (including the Trx gene) were excised from
pEG202 as EcoRI/NotI fragments and cloned into pGEX4T1 EcoRI/
NotI. To create GFP^peptide fusion proteins, the variable region of
the aptamers was ampli¢ed by polymerase chain reaction and cloned
as an EcoRI/XhoI fragment into pEGFP-C3 EcoRI/SalI.
2.2. Peptide synthesis
Peptide synthesis was performed on Fmoc-L-Met_PEG-PS resin
(Applied Biosystems) as previously described [20]. The Fmoc depro-
tection time was increased all the synthesis long (7^9 min) and a 5 min
capping by acetylation with 0.3 M acetyl imidazole in DMF was done
after coupling to prevent deleterious peptide synthesis.
The peptide was deprotected, puri¢ed and analysed as described
[20], except that dimethyl sul¢de (3%) was added to the deprotection
mixture to reduce methionine oxidation. FAB and MALDI mass
spectra (MH+=4423) and amino acid analyses after HCl hydrolysis
were in line with the expected structure.
2.3. In vitro GDP/GTP exchange assays
GTPase^GST fusion proteins were prepared, loaded with [3H]GDP,
and the guanine nucleotide release assay was performed as described
[5], using recombinant GST^TrioGEFD2 (aa 1848^2298), TrioDH2
(aa 1848^2096), TrioGEFD1 (aa 1232^1629), Kalirin GEFD2
(aa 1850^2190), Dbl (aa 495^826), Lbc (aa 1^424) [22], p63RhoGEF
(aa 149^374) and GST-tagged aptamers. For each point of the GDP-
release assay, 0.3 WM GTPase was mixed with or without 0.4 WM
GEF, and the reaction mix was ¢ltered after 0 min and 15 min re-
actions at 25‡C. The results are expressed as the ratio ‘exchange after
15 min over exchange after 0 min’ (% bound [3H]GDP^RhoA).
The time course of [35S]GTPQS binding was performed as described
previously [21]. Brie£y, 1 WM of GDP-loaded RhoA was mixed with
or without 1.5 WM TrioGEFD2 in the presence of 10 WM [35S]GTPQS
at 25‡C, and the reaction mix was ¢ltered after the indicated times.
To measure the e¡ect of the aptamers on the exchange activity, a
20-fold molar excess of GST-aptamer was pre-incubated with the
GEFs for 30 min on ice before the exchange assays were carried
out. For each experiment, data were obtained in triplicate.
2.4. Cell culture and transfection
COS-7 cells were maintained at 37‡C in the presence of 5% CO2 in
Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% foetal
bovine serum. PC12^E2 cells were maintained and plated on collagen-
coated 12 mm coverslips as described previously [16]. Transfection of
PC12 and COS-7 cells was performed using Lipofectamine Plus (Life
Technologies) according to the manufacturer’s protocol.
2.5. RhoA activity assay
The level of GTP-bound form of RhoA was measured as described
[23]. Brie£y, COS cells were transfected with TrioGEFD2 in the ab-
sence or in the presence of GFP^TRIAPK. 48 h after transfection, cell
lysates were subjected to GST pull-down, using the recombinant RBD
fragment of the RhoA-speci¢c e¡ector Rhotekin. The presence of
total RhoA and the GTP-bound form of RhoA in the samples was
revealed on a Western blot using a monoclonal anti-RhoA antibody
(Santa Cruz Biotechnology).
2.6. Immuno£uorescence microscopy
After transfection and di¡erentiation, PC12 cells were ¢xed and
permeabilised as described [16]. Expression of proteins was visualised
as indicated in the ¢gure legend, and cells were observed under a
DMR Leica microscope using a 40U planapochromat lens. Images
were recorded using a Hamamatsu CCD camera. All transfections
were repeated at least three times, and an average of 200 cells was
counted each time. Cells with neurites are de¢ned as cells with neu-
rites of at least twice the length of the cell body.
3. Results
3.1. The aptamer TRIAPK inhibits the in vitro exchange
activity of TrioGEFD2 towards RhoA
In order to identify speci¢c inhibitors of TrioGEFD2, we
used a recently developed strategy derived from the yeast two-
hybrid system, where the cDNA library of preys has been
replaced by a combinatorial library of short peptides (20 aa)
in fusion with the bacterial protein Trx [18,24]. This strategy
has been successfully used to isolate speci¢c inhibitors of the
cyclin-dependent kinases [18], the cell cycle transcription fac-
tor E2F [25] or the viral HPV16 E6 oncoprotein and HBV
core protein [26,27]. Using TrioGEFD2 as a bait, 2U106
transformants were screened and, among the aptamers bind-
ing to TrioGEFD2 in yeast, three were selected for further
analysis. These aptamers (TRIAPK, TRIAPL, TRIAPQ) were
tested against di¡erent baits as indicated in Fig. 1A: they
interacted speci¢cally with TrioGEFD2 and not with other
Rho^GEF members such as Dbl and Vav, nor with a non-
related protein such as Cdc2. TRIAPL and TRIAPQ only
bound to the DH2PH2 module, whereas TRIAPK also inter-
acted with the DH2 catalytic domain.
The predicted amino acid sequence of the variable moiety
of the aptamers is shown in Fig. 1B. These sequences showed
no homology to each other nor to any sequence in the data-
bases.
As described earlier, TrioGEFD2 displays speci¢c exchange
activity on RhoA [5] and not Rac or Cdc42. We next tested
whether the TrioGEFD2-binding aptamers could inhibit the
catalytic activity of TrioGEFD2 towards RhoA. For this pur-
pose, the aptamers were expressed and puri¢ed from bacteria
as GST fusion proteins and tested in an in vitro GEF assay,
using recombinant TrioGEFD2 and RhoA proteins. The
Rho^GEF activity was tested on [3H]GDP-loaded RhoA in
the presence of non-labelled GTP, where the catalytic activity
of TrioGEFD2 was measured by the decrease of the GTPase-
associated radioactivity. Preincubation (30 min) of a 20-fold
molar excess of GST^TRIAPK with TrioGEFD2 signi¢cantly
inhibited its in vitro catalytic activity towards RhoA, whereas
the same amount of GST^TRIAPL, GST^TRIAPQ or GST^
Trx had no e¡ect (Fig. 1C). The full inhibitory e¡ect of
TRIAPK on TrioGEFD2 catalytic activity was also obtained
with only a 5-min-preincubation time, suggesting that the
TRIAPK/GEFD2 complex had already reached an equilibri-
um (data not shown). In addition, GST^TRIAPK inhibited
both TrioGEFD2 and TrioDH2 exchange activities, which is
consistent with the fact that TRIAPK also recognised the
DH2 catalytic domain in yeast.
3.2. Characterisation of the inhibitory e¡ect of TRIAPK on
TrioGEFD2 catalytic activity
To characterise the inhibitory e¡ect of TRIAPK over time,
we performed a time course of the GDP-release assay. Trio-
GEFD2 stimulated complete GDP-dissociation from RhoA
within 20 min, whereas preincubation of GST^TRIAPK
with TrioGEFD2 prevented the GDP-dissociation at any
time points tested (Fig. 2A). To show that our GDP-dissoci-
ation assay re£ected the GDP/GTP exchange, we also per-
formed [35S]GTPQS binding experiments on RhoA. As shown
in Fig. 2B, GST^TRIAPK inhibited the [35S]GTPQS binding
on RhoA stimulated by GEFD2, while TRIAPL had no e¡ect.
Moreover, inhibition of GEFD2 exchange activity by GST^
TRIAPK was concentration-dependent, with an apparent half-
inhibitory concentration of around 4 WM (Fig. 2C).
3.3. Speci¢city of TRIAPK inhibition
We next investigated whether TRIAPK inhibition was spe-
ci¢c of TrioGEFD2 by testing the e¡ect of GST^TRIAPK on
other Rho^GEFs that display in vitro exchange activity on
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RhoA. We used di¡erent concentrations of Rho^GEFs to
yield a similar nucleotide exchange e⁄ciency, allowing us to
compare the inhibitory e¡ect of TRIAPK on the di¡erent
GEF activities. The exchange activities of Lbc and Dbl (Fig.
2D and data not shown) were not a¡ected by GST^TRIAPK.
We then tested the e¡ect of GST^TRIAPK on the catalytic
activity of Rho^GEFs that display a high sequence similarity
with TrioGEFD2: the recently identi¢ed RhoA-speci¢c
p63RhoGEF [28] (71.5% identity with TrioGEFD2) and the
second Rho^GEF domain of the Trio family member Kalirin
(KalGEFD2; 65% identity with TrioGEFD2). GST^TRIAPK
had no e¡ect on the catalytic activity of p63RhoGEF and
Fig. 1. TRIAPK inhibits TrioGEFD2-exchange activity on RhoA in vitro. A: Isolation of aptamers (TRIAPK, TRIAPL, and TRIAPQ) binding
to TrioGEFD2. The selected aptamers binding to TrioGEFD2 were tested for a speci¢c interaction against di¡erent baits. Aptamers were co-
transformed in yeast with either empty vector, Trio constructs (DH2PH2, DH2 or PH2), unrelated Rho^GEFs (Dbl, Vav) or Cdc2, and moni-
tored for growth on a selective medium. Trx represents the Trx protein with no inserted peptide. B: Predicted amino acid sequence of the vari-
able moiety of the selected aptamers. TRIAPK is a 42mer, TRIAPL is a 20mer, whereas TRIAPQ is a 16mer. C: TRIAPK is a potent inhibitor
of TrioGEFD2 activity. A 20-fold molar excess (8 WM) of GST aptamers TRIAPK, TRIAPL, TRIAPQ or the empty Trx were pre-incubated
30 min at 4‡C with 0.4 WM GST^GEFD2 or 0.4 WM GST^DH2, as indicated, before adding 0.3 WM of [3H]GDP-loaded GST^RhoA. The
exchange activity was monitored by the decrease of [3H]GDP-bound RhoA after 15 min (see Section 2). The amount of [3H]GDP-bound
RhoA incubated without GEF was de¢ned as 100%. The values and error bars are calculated from at least three independent experiments.
FEBS 26233 5-7-02
S. Schmidt et al./FEBS Letters 523 (2002) 35^42 37
Fig. 2. Characterisation of the inhibitory e¡ect of TRIAPK in vitro. A: Time of course of TrioGEFD2-induced guanine nucleotide release on
RhoA after preincubation of TrioGEFD2 with GST^Trx (R) or GST^TRIAPK (F). The spontaneous guanine nucleotide release on RhoA
without TrioGEFD2 was measured in the presence of GST^Trx (O) or GST^TRIAPK (E). The exchange activity was monitored by the de-
crease of [3H]GDP-bound RhoA at the indicated times as described in Fig. 1C. B: Kinetics of association of [35S]GTPQS to GDP-loaded
RhoA after preincubation of TrioGEFD2 with a 20-fold molar excess of GST^Trx (R), GST^TRIAPK (F) or GST^TRIAPL (b). O represents
the incubation of GDP-loaded RhoA with GST^Trx but not TrioGEFD2. C: TRIAPK inhibition of GEFD2 is dose-dependent. 0.4 WM GST^
GEFD2 was incubated with increasing amounts of GST (black bars), GST^TRIAPK (light grey bars), or GST^TRIAPL (dark grey bars), and
the exchange assay was then performed on 0.3 WM RhoA as described in Fig. 1C. D: TRIAPK inhibition is speci¢c of TrioGEFD2. To test
the speci¢city of TRIAPK inhibition in vitro, exchange experiments were performed with di¡erent RhoA-speci¢c GEFs: Trio GEFD2
(0.4 WM), Kalirin GEFD2 (KalGEFD2; 1.7 WM), p63RhoGEF (0.4 WM), Lbc (0.4 WM) and the RhoG-speci¢c GEF domain of Trio
(TrioGEFD1; 0.1 WM). Exchange assays were performed with the recombinant GEFs as described in Fig. 1C. We used di¡erent concentrations
of Rho^GEFs to yield a similar nucleotide exchange e⁄ciency. For each exchange factor, three independent experiments were done in the ab-
sence (black bar) or in the presence (light grey bar) of a 20-fold molar excess of TRIAPK.
FEBS 26233 5-7-02
S. Schmidt et al./FEBS Letters 523 (2002) 35^4238
partially inhibited KalGEFD2 exchange activity on RhoA. In
addition, GST^TRIAPK did not block TrioGEFD1 activity
on RhoG or Rac (Fig. 2Dand data not shown).
3.4. TRIPK has the same inhibitory e¡ect as TRIAPK
TRIAPK blocked TrioGEFD2 exchange activity when its
conformation was constrained by the presence of Trx. To
evaluate the role of the Trx constraint in inhibition, we tested
whether TrioGEFD2 activity could be blocked by a synthetic
peptide of 42 aa, TRIPK, corresponding to the variable region
of TRIAPK. At the same dosage (20-fold molar excess),
TRIPK was as potent as TRIAPK in blocking the in vitro
TrioGEFD2 exchange activity, suggesting that the Trx scaf-
fold is not required for the TRIAPK inhibitory e¡ect on Trio-
GEFD2 catalytic activity (compare Figs. 3A and 1C).
3.5. Minimal TRIPK sequence requirements for inhibition of
TrioGEFD2 exchange activity
In order to map the sequence of TRIPK responsible for the
inhibition of TrioGEFD2 activity, we tested di¡erent trunca-
tions of the TRIPK variable region on the inhibition of the in
vitro TrioGEFD2 exchange activity (Fig. 3B). Deletion of the
¢rst eight amino acids of TRIAPK (TRIAPK 9^42) did not
alter its inhibitory e¡ect, while deletion of two additional
amino acids (TRIAPK 11^42) completely abrogated its e¡ect
(Fig. 3A, B). Amino acids 9^36 displayed full inhibitory ac-
tivity when constrained by the Trx sca¡old, but not as a free
peptide (TRIPK 9^36; Fig. 3B). These data suggested that the
minimal sequence required for TrioGEFD2 inhibition is
aa 9^36. However, in contrast to the full length TRIAPK,
the TRIAPK 9^36 inhibitory e¡ect was dependent on the
presence of the sca¡old.
3.6. Inhibition by TRIPK of TrioGEFD2-mediated RhoA
activation in intact cells
We next wanted to determine the e¡ect of TRIPK on
GEFD2-mediated RhoA activation in intact cells. We ¢rst
checked whether TRIPK could bind to TrioGEFD2 in mam-
malian cells. For that purpose, we designed vectors expressing
the variable regions of TRIPK fused to GFP. GFP or GFP^
Fig. 3. Characterisation of the TRIPK inhibitory properties. A: TRIPK shows the same inhibitory properties as TRIAPK. A 42-aa peptide cor-
responding to the variable moiety of TRIAPK, TRIPK, and a deletion of TRIAPK, TRIAPK 11^42, were tested in exchange assays for their
ability to block TrioGEFD2 activity on RhoA. GEF assays were performed as described in Fig. 1C in the absence or in the presence of 8 WM
of the di¡erent inhibitors, as indicated. B: Mapping of the minimal region of TRIAPK required for inhibition. Deletion mutants were created
in the variable region of TRIAPK (still inserted in the Trx sca¡old) or TRIPK, and tested for their ability to inhibit TrioGEFD2 activity in ex-
change assays (described in Fig. 1C). ++ represents the full retention of the inhibitory e¡ect, while 33 re£ects the loss of inhibition. Nd signi-
¢es not determined.
FEBS 26233 5-7-02
S. Schmidt et al./FEBS Letters 523 (2002) 35^42 39
FEBS 26233 5-7-02
S. Schmidt et al./FEBS Letters 523 (2002) 35^4240
TRIPK were co-expressed with TrioGEFD2 in COS cells, and
the protein interactions were studied by immunoprecipitation.
TrioGEFD2 was present in the GFP^TRIPK-immunoprecipi-
tates and not in the GFP-immunoprecipitates, indicating that
TRIPK interacts with TrioGEFD2 in mammalian cells (Fig.
4A). We then wanted to assess the inhibition by TRIPK of
TrioGEFD2-mediated activation of endogenous RhoA in in-
tact cells. To do so, we made use of a GST fusion protein of
the RhoA-speci¢c e¡ector Rhotekin (GST^RBD) in a pull-
down assay from COS cell lysates to detect the active GTP-
bound form of RhoA [23]. As shown in Fig. 4B, the activation
of RhoA by TrioGEFD2 was signi¢cantly inhibited by the co-
expression of GFP^TRIPK, showing that TRIPK is able to
inhibit TrioGEFD2 activity in intact cells.
Numerous reports have established Rho^GTPases as key
regulators of neuronal morphology [29]. In neuronal cell lines,
activation of RhoG, Rac and Cdc42 induces neurite out-
growth, while RhoA stimulation antagonises this e¡ect by
promoting neurite retraction [30^32]. The PC12 cell line is a
useful cellular model for studying NGF-induced neuronal dif-
ferentiation. As already described in other studies [30], we
observed that expression of an activated form of RhoA
(RhoAV14) in PC12 cells prevented NGF-induced neurite
outgrowth (Fig. 4D, black column). Similarly, we noticed
that expression of TrioGEFD2 and KalGEFD2 also pre-
vented NGF-induced neurite outgrowth, which is consistent
with their speci¢city for RhoA. For example, only 16% of
PC12 cells expressing HA^TrioGEFD2 extended neurites in
response to NGF (Fig. 4D, black column), whereas more than
50% of cells usually respond to NGF treatment (data not
shown). We then tested whether GFP^TRIPK could revert
the inhibitory e¡ect of TrioGEFD2 on NGF-induced neurite
outgrowth. The expression of GFP^TRIPK alone had no ef-
fect on the NGF-di¡erentiation signal (data not shown). In-
terestingly, co-expression of GFP^TRIPK with TrioGEFD2
reverted the Trio-dependent inhibition, since 45% of co-trans-
fected cells extended neurites upon NGF treatment, while this
reversion was not observed in presence of GFP alone or
GFP^TRIPL (Fig. 4C, D). Since TRIPK slightly inhibited
KalGEFD2 exchange activity in vitro, we tested whether
TRIPK was able to a¡ect KalGEFD2 activity in vivo. In
contrast to TrioGEFD2, neurite extension was similarly in-
hibited by KalGEFD2 either with or without GFP^TRIPK
co-expression (Fig. 4D). Taken together, these data show
that TRIPK speci¢cally inhibits the e¡ect of ectopically ex-
pressed TrioGEFD2 on PC12 cell morphology.
4. Discussion
In this study, we present the ¢rst isolation of a Rho^GEF
inhibitor, TRIPK, speci¢cally targeting the second Rho^GEF
domain of the multifunctional protein Trio. This inhibitor
binds to TrioGEFD2 in yeast and inhibits its in vitro catalytic
activity towards RhoA. It does not signi¢cantly a¡ect the
activity of other RhoA-speci¢c GEFs nor that of TrioGEFD1
towards RhoG, and thus seems to be speci¢c for TrioGEFD2.
We show that the inhibition of the catalytic activity by
TRIAPK is independent of the presence of the PH2 domain,
since both GEFD2 and DH2 activities are a¡ected. Given the
fact that TRIAPK strongly interacts with TrioDH2 in yeast
and that TRIAPK inhibition of TrioGEFD2 activity is dose-
dependent (IC50 = 4 WM), we suspect that TRIAPK competi-
tively inhibits the interaction of the DH2 domain with its
GTPase target. It is noteworthy, however, that the TRIPK
peptide sequence does not resemble any GTPase fragment
that could prevent the interaction between TrioGEFD2 and
its target. The mechanism of inhibition appears distinct from
that proposed for the inhibition of ADP-ribosylation factor
(Arf1) GTPase exchange factors by Brefeldin A [33]. Brefeldin
A dramatically a¡ects the structure of the Golgi apparatus by
its capacity to stabilise an abortive ARF^GDP^GEF complex
rather than preventing its formation. Thus, our inhibitor may
represent the ¢rst example of a peptide acting as a competitive
inhibitor between a GEF and its GTPase target.
In addition, TRIPK inhibition is not dependent on the Trx
sca¡old, suggesting that TRIPK adopts a functional three-di-
mensional structure on its own. Full inhibition can be
achieved with TRIPK aa 9^36, but only when linked to the
Trx sca¡old. We propose that this 28-aa motif represents the
active core for inhibition, while the £anking sequences stabi-
lise its conformation. Characterising the molecular determi-
nants underlying TRIPK inhibition of DH2-mediated catalysis
will considerably aid our dissection of the mechanism of nu-
cleotide exchange and speci¢city. Indeed, although the numer-
ous members of the Rho^GEF family display distinct patterns
of speci¢city for their GTPase targets, little is known about
how this speci¢city is achieved at a molecular level.
Trio is the founding member of an emerging family of
Rho^GEFs, including rat Kalirin, that possesses two GEF
domains of distinct speci¢city. We found that TRIPK slightly
inhibited the in vitro catalytic activity of Kalirin GEFD2.
This is not surprising, considering the strong homology be-
tween the catalytic DH domains of Trio and Kalirin, espe-
6
Fig. 4. Inhibition by TRIPK of TrioGEFD2-mediated RhoA activation in intact cells. A: Interaction of HA^TrioGEFD2 with GFP^TRIPK in
COS cells. HA^TrioGEFD2 was co-expressed with either GFP^TRIPK or GFP alone. The upper panel represents the immunoprecipitation
with the anti-GFP antibody (IP: K-GFP) followed by a Western blot using the anti-HA antibody (WB: K-HA), and the lower panels represent
the expression of the proteins in the cell lysates. B: Inhibitory e¡ect of TRIPK on TrioGEFD2-mediated RhoA activation in intact cells using
the RhoA activity assay. COS cells were transfected with TrioGEFD2, GFP^TRIPK or both. Cell lysates were subjected to GST pull-down us-
ing the recombinant RBD fragment of the RhoA-speci¢c e¡ector Rhotekin. The presence of the GTP-bound form of RhoA and of total RhoA
protein was detected using a monoclonal anti-RhoA antibody and is represented in the upper two panels. GFP^TRIPK and TrioGEFD2 ex-
pression in the cell lysates is shown in the lower two panels. Quanti¢cation of the RhoA activity assay is shown in the right part of the ¢gure.
C: Inhibition by TRIPK of the TrioGEFD2 e¡ect on neuronal morphology. Shown are immuno£uorescence images of PC12 cells co-transfected
with HA^TrioGEFD2 and either GFP^TRIPK (panels d^f) or GFP alone (panels a^c). After 48 h of expression, cells were treated for 16 h
with NGF (50 ng/ml) and ¢xed. Expression of GFP and GFP^TRIPK was visualised directly (a, d), whereas overexpressed TrioGEFD2 was de-
tected using the 12CA5 anti-HA antibody followed by AMCA-conjugated anti-mouse IgG (b, e). Filamentous actin was stained with Rho-
damine-conjugated Phalloidin (c, f). Scale bar: 20 Wm. D: Quanti¢cation of the TRIPK inhibition of TrioGEFD2-induced neuronal morphol-
ogy. Cells were transfected with HA-tagged TrioGEFD2, myc-tagged KalGEFD2 or RhoAV14, and with either GFP^TRIPK, GFP^TRIPL or
GFP alone. Cells were processed as described in (C) and the number of co-expressing cells with neurites was counted. Note that only the Trio-
GEFD2 e¡ect is reversed by TRIPK (light grey bar).
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cially in the conserved regions CR1 and CR3 predicted to
interact with the GTPase. Nevertheless, TRIPK e⁄ciently in-
terfered with the e¡ect on neuronal morphology of Trio-
GEFD2 but not of Kalirin GEFD2, indicating TRIPK is func-
tionally a very speci¢c inhibitor of the RhoA-speci¢c DH
domain of Trio. Considering the fact that Trio and the
brain-speci¢c Kalirin have putative redundant functions in
the nervous system, TRIPK thus represents a means to deci-
pher their respective functions in this system.
Rho^GEFs such as Trio display several domains whose
relative contribution to the function of the protein is not al-
ways understood. Developing aptamer inhibitors that target a
precise domain represents an alternative inactivation strategy
to the more classical knock-out techniques that target the
activity or the expression of the entire gene product. We re-
port here such an inhibitor that is a potent and speci¢c in-
hibitor of TrioGEFD2 activity in living cells: (i) TRIPK co-
immunoprecipitates with TrioGEFD2 and inhibits Trio-
GEFD2-mediated activation of RhoA in COS cells ; (ii)
TRIPK speci¢cally inhibits the e¡ect of ectopic TrioGEFD2
ectopic expression on neuronal morphology. It thus represents
a powerful tool to determine precisely the role of Trio-
GEFD2, whose function in the context of the full length pro-
tein remains elusive.
Finally, this is the ¢rst report of a speci¢c in vivo inhibitor
of a Rho^GEF. Our peptide aptamer therefore represents an
important step in the design of inhibitors speci¢c for the ex-
panding family of Rho^GEFs.
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